A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Phase of Trial: Phase III
Latest Information Update: 02 May 2017
At a glance
- Drugs Tazarotene/ulobetasol (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors Valeant Pharmaceuticals International
- 26 Apr 2017 Status changed from active, no longer recruiting to completed.
- 10 Jan 2017 Results published in the Valeant Pharmaceuticals International Media Release
- 10 Jan 2017 Primary endpoint has been met. (Treatment success rate), as reported by a Valeant Pharmaceuticals International Media Release.